In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Pyxis Oncology Inc (NASDAQ: PYXS) closed at $3.62 in the last session, up 7.74% from day before closing price of $3.36. In other words, the price has increased by $7.74 from its previous closing price. On the day, 0.51 million shares were traded. PYXS stock price reached its highest trading level at $3.69 during the session, while it also had its lowest trading level at $3.3387.
Ratios:
We take a closer look at PYXS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.53 and its Current Ratio is at 9.53. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on August 08, 2024, initiated with a Buy rating and assigned the stock a target price of $10.
On February 09, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $8.BTIG Research initiated its Buy rating on February 09, 2024, with a $8 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 28 ’23 when Connealy Pamela Ann bought 8,000 shares for $1.87 per share. The transaction valued at 14,960 led to the insider holds 818,532 shares of the business.
Wadhane Jitendra bought 2,500 shares of PYXS for $4,675 on Sep 27 ’23. The Chief Accounting Officer now owns 226,937 shares after completing the transaction at $1.87 per share. On Sep 27 ’23, another insider, Connealy Pamela Ann, who serves as the CFO and COO of the company, bought 6,426 shares for $1.85 each. As a result, the insider paid 11,868 and bolstered with 810,532 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PYXS now has a Market Capitalization of 213370752 and an Enterprise Value of 78518920. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.21 while its Price-to-Book (P/B) ratio in mrq is 1.26. Its current Enterprise Value per Revenue stands at 4.863 whereas that against EBITDA is -1.243.
Stock Price History:
Over the past 52 weeks, PYXS has reached a high of $6.85, while it has fallen to a 52-week low of $1.35. The 50-Day Moving Average of the stock is 5.56%, while the 200-Day Moving Average is calculated to be 2.57%.
Shares Statistics:
According to the various share statistics, PYXS traded on average about 600.06K shares per day over the past 3-months and 515680 shares per day over the past 10 days. A total of 58.94M shares are outstanding, with a floating share count of 46.32M. Insiders hold about 21.42% of the company’s shares, while institutions hold 52.77% stake in the company. Shares short for PYXS as of 1722384000 were 3994384 with a Short Ratio of 6.66, compared to 1719532800 on 2314100. Therefore, it implies a Short% of Shares Outstanding of 3994384 and a Short% of Float of 8.51.
